EGFR and non-small cell lung carcinoma: No OS benefit was shown with pembrolizumab over docetaxel in NSCLC patients with EGFR mutations (HR = 0.88 95% CI:0.45–1.70) vs. WT (HR = 0.66, 95% CI:0.55–0.80)